SCHEMBL6074141

SCHEMBL6074141

CC1CN(c2ccc(Nc3ncc4ccc(NC(=O)NC5CCCCC5)nc4n3)cc2)CC(C)N1C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 1/20 0.41
CDK4 P11802 3/20 0.41
CCND1 P24385 3/20 0.41
CCND3 P30281 2/20 0.41
CCND2 P30279 1/20 0.41
NPR3 P17342 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
SYK P43405 9/20 0.39
EGFR P00533 1/20 0.38
CDK2 P24941 2/20 0.37
LRRK2 Q5S007 1/20 0.37
CCNK O75909 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK9 P50750 1/20 0.37
CDK6 Q00534 1/20 0.37
JAK3 P52333 1/20 0.37
GAA P10253 1/20 0.37
CCNE1 P24864 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6074137 1.00 AURKB (0.41) AURKBCDK4CCND1CCND3CCND2
SCHEMBL6073385 0.88 SYK (0.40) CDK4CCND1CCND3CCND2SYK
SCHEMBL6073388 0.88 SYK (0.40) CDK4CCND1CCND3CCND2SYK
SCHEMBL6073880 0.88 CDK4 (0.54) AURKBCDK4CCND1CCND3CCND2
SCHEMBL6073855 0.87 CDK4 (0.54) AURKBCDK4CCND1CCND3CCND2
SCHEMBL6073827 0.87 CCND3 (0.41) AURKBCDK4CCND1CCND3CCND2
SCHEMBL6073780 0.87 CCND3 (0.41) AURKBCDK4CCND1CCND3CCND2
SCHEMBL6073783 0.87 CCND3 (0.41) AURKBCDK4CCND1CCND3CCND2
SCHEMBL6073824 0.87 CCND3 (0.41) AURKBCDK4CCND1CCND3CCND2
SCHEMBL6074026 0.84 CDK4 (0.49) AURKBCDK4CCND1CCND3CCND2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 AURKB 308/4885CDK4 19/4885CCND1 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.